Promoting safe and effective genetic tests in the United States: Work of the Task Force on Genetic Testing

Clinical Chemistry

Volumn 45, Issue 5, 1999, Pages 732-738

  Holtzman, Neil A ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC ACCURACY; GENETIC COUNSELING; GENETIC DISORDER; HEALTH CARE POLICY; HUMAN; REVIEW; UNITED STATES;

EID: 0032949239     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.5.732     Document Type: Review

References (26)

1. 1. Holtzman NA. Benefits and risks of emerging genetic technologies: the need for regulation. Clin Chem 1994;40:1652-7.
2. 2. American Society of Human Genetics Ad Hoc Committee on Breast and Ovarian Cancer Screening. Statement of The American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition. Am J Hum Genet 1994;55:1-4.
3. 3. National Advisory Council for Human Genome Research. Statement on use of DNA testing for presymptomatic identification of cancer risk. JAMA 1994;271:785.
4. 4. American College of Medical Genetics. Statement on use of apolipoprotein E testing for Alzheimer disease. JAMA 1995;274:1627-9.
5. 5. National Institute on Aging. Apolipoprotein E genotyping in Alzheimer's disease. Lancet 1996;347:1091-5.
6. 6. Holtzman NA, Hilgartner S. State of the art of genetic testing in the United States: survey of biotechnology companies and nonprofit clinical laboratories and interviews of selected organizations. In: Holtzman NA, Watson MS, eds. Promoting safe and effective genetic testing in the United States. Final report of the Task Force on Genetic Testing. Baltimore, MD: Johns Hopkins University Press, 1998:99-124.
7. 7. Holtzman NA, Watson MS, eds. Promoting safe and effective genetic testing in the United States. Final report of the Task Force on Genetic Testing. Baltimore, MD: Johns Hopkins University Press, 1998.
8. 8. National Institutes of Health. Proposed recommendations of the Task Force on Genetic Testing: notice of meeting and request for comment. Fed Regist 1997;62:4539-47.
9. 9. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
10. 10. Laken SJ, Petersen GM, Gruber SB, Oddoux C, Ostrer H, Giardiello FM, et al. Familial colorectal cancer in Ashkenazim clue to a hypermutable tract in APC. Nat Genet 1997;17:79-83.
11. 11. Petrukhin L, Dangel J, Vanderveer L, Costalas J, Bellacosa AG, Daly GM, A KG. The 11307K APC mutation does not predispose to colorectal cancer in Jewish Ashkenazi breast and breast-ovarian cancer kindreds. Cancer Res 1997;57:5480-4.
12. 12. Woodage T, King SM, Wacholder S, Hartge P, Struewing JP, McAdams M, et al. The APC 11307K allele and cancer risk in a community-based study of Ashkenazi Jews [Letter]. Nat Genet 1998;20:62-5.
13. 13. Office of Protection from Research Risks. Protecting human research subjects. Institutional Review Board guidebook. Washington, DC: US Government Printing Office, 1993.
14. 14. Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77-84.
15. 15. US Preventive Services Task Force. Guide to clinical preventive services, 2nd ed. Alexandria, VA: International Medical Publishing, 1996.
16. 16. Schwartz M. Genetic testing and the Clinical Laboratory Improvement Amendments of 1988: present and future. Clin Chem 1999;45:739-45.
17. 17. Cho MK, Arruda M, Holtzman NA. Educational material about genetic tests: does it provide key information for patients and practitioners? Am J Med Genet 1997;73:314-20.
18. 18. Cho MK, Arruda M, Holtzman NA. Informational materials about genetic tests. In: Holtzman NA, Watson MS, eds. Task Force on Genetic Testing: promoting safe and effective genetic testing in the United States. Final report of the Task Force on Genetic Testing, Baltimore, MD: Johns Hopkins University Press, 1998: 125-35.
19. 19. Genetics & IVF Institute. Breast and/or ovarian risk in Jewish women: role of mutations in the BRCA1 and BRCA2 genes. Fairfax, VA: Genetics & IVF Institute, 1996.
20. 20. University of Pennsylvania. Genetic testing for breast and ovarian cancer risk. An information guide. Philadelphia, PA: Molecular Diagnosis Laboratory, University of Pennsylvania, 1996.
21. 21. Myriad. A reference for health care professionals. Salt Lake City, UT: Myriad Genetic Laboratories, 1996.
22. 22. OncorMed. Hereditary breast cancer: questions and answers for physicians. Gaithersburg, MD: OncorMed, 1996.
23. 23. Hofman KJ, Tambor ES, Chase GA, Geller G, Faden RR, Holtzman NA. Physicians' knowledge of genetics and genetic tests. Acad Med 1993;68:625-31.
24. 24. Hayflick SJ, Eiff P, Carpenter L, Steinberger J. Primary care physicians' utilization and perceptions of genetics services. Genet Med 1998;1:13-21.
25. 25. Giardiello FM, Brensinger JD, Petersen GM, Luce MC, Hylind LM, Bacon JA, et al. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med 1997;336:823-7.
26. 26. Task Force on Genetic Testing. Response of the Task Force to the Food and Drag Administration's proposed rule on analyte specific reagents. In: Holtzman NA, Watson MS, eds. Promoting safe and effective genetic testing in the United States. Final report of the Task Force on Genetic Testing. Baltimore, MD: Johns Hopkins University Press, 1998:93-8.